Research Analysts Offer Predictions for ABUS FY2025 Earnings

Key Points

• Chardan Capital raised its FY2025 earnings estimates for Arbutus Biopharma to ($0.18) per share, up from a previous forecast of (0.25), while maintaining a "Buy" rating on the stock with a price target of $5.00.
• Arbutus Biopharma reported a quarterly earnings beat with $0.01 per share, exceeding analyst estimates of ($0.02), and achieved revenue of $10.74 million versus expected $2.21 million.
• Institutional interest in Arbutus Biopharma has increased, with several hedge funds significantly raising their stakes in the company during the second quarter.

Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) - Equities researchers at Chardan Capital increased their FY2025 earnings per share estimates for Arbutus Biopharma in a research report issued on Monday, August 11th. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will post earnings of ($0.18) per share for the year, up from their prior estimate of ($0.25). Chardan Capital has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Arbutus Biopharma's current full-year earnings is ($0.39) per share. Chardan Capital also issued estimates for Arbutus Biopharma's FY2026 earnings at ($0.17) EPS.

Separately, Wall Street Zen raised Arbutus Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $5.50.

Arbutus Biopharma Stock Performance

Shares of Arbutus Biopharma stock traded up $0.0650 during mid-day trading on Thursday, hitting $3.4450. 407,278 shares of the stock were exchanged, compared to its average volume of 862,431. Arbutus Biopharma has a 12 month low of $2.70 and a 12 month high of $4.72. The company has a 50-day simple moving average of $3.31 and a 200 day simple moving average of $3.31. The company has a market capitalization of $660.40 million, a P/E ratio of -11.88 and a beta of 0.86.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. Arbutus Biopharma had a negative net margin of 352.24% and a negative return on equity of 59.28%. The company had revenue of $10.74 million during the quarter, compared to analyst estimates of $2.21 million.

Institutional Investors Weigh In On Arbutus Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in shares of Arbutus Biopharma by 900.4% in the fourth quarter. JPMorgan Chase & Co. now owns 896,258 shares of the biopharmaceutical company's stock valued at $2,931,000 after purchasing an additional 806,672 shares in the last quarter. Franklin Resources Inc. bought a new position in Arbutus Biopharma in the 4th quarter worth about $301,000. Geode Capital Management LLC grew its holdings in Arbutus Biopharma by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 3,482,136 shares of the biopharmaceutical company's stock valued at $11,390,000 after buying an additional 33,536 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Arbutus Biopharma by 44.6% during the fourth quarter. Wells Fargo & Company MN now owns 70,599 shares of the biopharmaceutical company's stock valued at $231,000 after buying an additional 21,768 shares during the period. Finally, Bank of Montreal Can increased its position in shares of Arbutus Biopharma by 3.5% during the fourth quarter. Bank of Montreal Can now owns 455,880 shares of the biopharmaceutical company's stock valued at $1,491,000 after buying an additional 15,567 shares during the period. Institutional investors own 43.79% of the company's stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.